The number of COVID-19 indicated medical devices gaining approval in Q3 2022 saw a 83% drop when compared with Q2 2022, according to GlobalData’s medical devices marketed products database
Compared with Q3 2021, the number of COVID-19 indicated medical devices gaining approval in Q3 2022 saw a 89% drop globally.
North America tops COVID-19 approved medical devices activity
Comparing COVID-19 medical device approvals activity in different regions of the globe, North America held the top position for approved products (64%) in Q3 2022, followed by Europe (24%), and Asia-Pacific (12%).
On a country level, the US had the most COVID-19 approved medical devices during the quarter, representing the largest share (44%) of the global market. In second place was Canada with a share of 19%, followed by United Kingdom with 11%.
COVID-19 marketed medical devices: Development activity in Q3 2022
GlobalData’s database indicated that CE-IVD marketed medical devices that addressed the COVID-19 pandemic accounted for 22% of medical devices in Q3 2022, compared with 36% in Q2 2022.
510(k) have become more common during the COVID-19 pandemic, as an expeditious mechanism to bring therapeutic devices to market more quickly than normal device approvals.
Company-developed COVID-19 medical devices lead in Q3 2022
GlobalData’s databases indicated that company-developed medical devices accounted for a 100% share of approved COVID-19 devices globally during Q3 2022, while institute-developed marketed products held the remaining share.
The quarterly average for Q3 2022 saw 100% of approved COVID-19 indicated devices originating from private and public companies, and 0% from institutes.
The Covid-19 medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.